Serge P Scherrer

Biography

"NanoString Technologies is a provider of Life Science tools that enable a wide variety of Basic Research, Translational Medicine and In Vitro Diagnostics applications. Based on the company's digital barcoding technologies, its nCounter® Analysis Systems have been cited in more than 1,300 peer-reviewed publications since 2008. These Systems offer cost-effective and highly simplified workflows to simultaneously profile the expression of hundreds of genes, proteins, miRNAs, copy number variations or fusion genes, with high sensitivity and precision, in a single experiment. The latest and affordable nCounter SPRINT Profiler includes microfluidic cartridges for true walk-away sample prep and data analysis. Setup takes only 15 minutes: pipette 4 times, load the cartridge and launch the run! NanoString’s novel and upcoming nCounter Vantage™ assays, combined with the Biologist-friendly nSolver Software, enable multiplexed, digital analysis of DNA, RNA, and Protein simultaneously for a single sample to power Cancer Research with 3D Biology™, including Immuno-Oncology. Leading Researchers and Institutions worldwide are finding that NanoString's nCounter® Systems provide the ideal platforms on which to validate their Discoveries and translate them into clinically useful diagnostic assays. They are uniquely positioned to support translational research because they provides more reproducible results than methods requiring amplification, and generate high-quality data from the compromised and challenging sample types common in clinical research, including FFPE tissues. The nCounter® Dx FLEX-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay has been the first FDA 510(k)-cleared assay to be marketed by NanoString. In addition, the Company is collaborating with multiple Biopharmaceutical Companies in the development of CDx tests for various cancer therapies, helping to realize the promise of Personalized Oncology and Immunotherapy."

Research Interest

NanoString's nCounter® Systems provide the ideal platforms on which to validate their Discoveries and translate them into clinically useful diagnostic assays